Thymohydroquinone

Thymohydroquinone is a naturally occurring monoterpenoid quinone derived primarily from Nigella sativa (black seed) that exerts its effects through inhibition of acetylcholinesterase, antioxidant radical scavenging, and disruption of microbial cell membrane integrity. Current evidence is largely preclinical, with in vitro and animal studies demonstrating antimicrobial, anti-inflammatory, and potential anticancer properties.

Origin & History

Thymohydroquinone is a naturally occurring monoterpene phenol (C₁₀H₁₄O₂) found primarily in thyme oil from Thymus vulgaris, as well as in oregano (Origanum spp.) and Calocedrus decurrens. It features a benzene ring with two hydroxyl groups and occurs naturally in the essential oils of these plants.

Historical & Cultural Context

No traditional or historical medicinal uses specific to thymohydroquinone are documented. While related compound thymoquinone from similar plants has traditional uses as an antihypertensive and digestive aid (PubMed PMID: 37605475), this does not apply directly to thymohydroquinone.

Health Benefits

• Antioxidant properties that protect against oxidative stress (preclinical evidence only)
• Anti-inflammatory effects demonstrated in laboratory studies (preclinical evidence only)
• Antimicrobial activity shown in vitro (preclinical evidence only)
• Cancer cell inhibition with IC50 values of 2.4-15.9 μM (in vitro studies only, no human trials)
• Potential enzyme modulation targeting oxidoreductases and matrix metalloproteinases (mechanism studies only)

How It Works

Thymohydroquinone acts as a potent inhibitor of acetylcholinesterase (AChE), preventing the breakdown of acetylcholine and thereby modulating cholinergic neurotransmission. It also scavenges reactive oxygen species (ROS) by donating hydrogen atoms through its hydroquinone moiety, reducing oxidative damage to lipids, proteins, and DNA. Additionally, it suppresses pro-inflammatory mediators by downregulating NF-κB signaling and inhibiting cyclooxygenase (COX) enzyme activity, limiting prostaglandin synthesis.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on thymohydroquinone. All available evidence comes from preclinical studies including in vitro cancer inhibition research (Cancer Res. 2002; Cancer Cell 2004; Biochem. Pharmacol. 2010), though these citations lack PubMed PMIDs and involve only laboratory or animal models.

Clinical Summary

No peer-reviewed human clinical trials have been conducted specifically on isolated thymohydroquinone as of the current literature. Preclinical in vitro studies have reported cancer cell inhibition with IC50 values in the low micromolar range (approximately 2.4–10 µM) against various tumor cell lines, including breast and colon cancer cells. Animal studies using rodent models have demonstrated anti-inflammatory and neuroprotective effects at doses ranging from 10 to 100 mg/kg body weight. The overall evidence base remains at an early preclinical stage, and conclusions about human efficacy cannot be drawn without controlled clinical trials.

Nutritional Profile

Thymohydroquinone (THQ) is a pure bioactive compound (C10H14O2, molecular weight 166.22 g/mol), not a whole food ingredient, and therefore has no conventional macronutrient or micronutrient profile. It is a monoterpenoid hydroquinone derivative naturally occurring in Nigella sativa (black seed) essential oil at concentrations of approximately 0.2–0.5% of total oil composition, alongside thymoquinone and thymohydroquinone dimethyl ether. As an isolated compound: no protein, carbohydrate, fiber, or fat content is applicable. Bioactive profile centers on its phenolic hydroquinone core structure, which confers electron-donating antioxidant capacity. LogP (lipophilicity) is estimated at approximately 2.8–3.2, suggesting moderate lipid solubility and potential for passive membrane permeability. Oral bioavailability data in humans is not established; preclinical studies suggest hepatic first-pass metabolism may produce conjugated sulfate and glucuronide metabolites. In Nigella sativa oil as a source matrix, THQ co-occurs with thymoquinone (~0.5–1.5% of oil), carvacrol, and p-cymene. No clinically validated dosing concentration or recommended intake level has been established for isolated THQ in humans.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials have not been conducted. Commercial forms show 99-99.6% purity in solid preparations, but therapeutic doses have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Thymol, carvacrol, rosmarinic acid, quercetin, vitamin E

Safety & Interactions

Thymohydroquinone has not been evaluated in formal human safety or toxicology trials as an isolated compound, making definitive side effect profiles difficult to establish. Because it inhibits acetylcholinesterase, concurrent use with cholinesterase inhibitor medications such as donepezil or rivastigmine may produce additive cholinergic effects, including nausea, bradycardia, and excessive secretions. Its presence in Nigella sativa oil at typical dietary concentrations is generally considered safe, but concentrated supplemental extracts carry unknown risk, particularly for pregnant or breastfeeding individuals who should avoid isolated thymohydroquinone supplements until safety data exist. Individuals on anticoagulant or antiplatelet therapy should exercise caution, as Nigella sativa compounds have demonstrated platelet aggregation inhibition in preclinical models.